Return to homepagePandemic Pact

PARTNERS trial

Grant number: 354078/Z/26/Z

Grant search

Key facts

  • Disease

    Ebola, Marburg virus disease, Other

  • Start & end year

    2026
    2027

  • Known Financial Commitments (USD)

    $2,904,550.87

  • Funder

    Wellcome Trust

  • Principal Investigator

    Prof Dr Amanda Rojek

  • Research Location

    United Kingdom

  • Lead Research Institution

    University of Oxford

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

PARTNERS is an acronym for 'Platform Adaptive Randomised Trial for NEw and Repurposed Filovirus treatmentS'. PARTNERS is a multi-country, multi-outbreak randomised adaptive platform trial of potential treatments for filovirus disease. This includes Ebola disease (Zaire, Sudan and Bundibugyo species), Marburg disease, and unspecified and emergent filovirus diseases. The primary aim is to identify the effect of included therapies on all-cause mortality at 28 days after randomisation in patients admitted to a healthcare facility with filovirus disease. The treatment comparisons included in the trial are determined by expert consultations convened by WHO.